Ironwood Pharmaceuticals
IRWD
221 hedge funds and large institutions have $2.09B invested in Ironwood Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 67 increasing their positions, 78 reducing their positions, and 29 closing their positions.
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
4% more funds holding
Funds holding: 212 → 221 (+9)
5% more capital invested
Capital invested by funds: $2B → $2.09B (+$92.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.39% less ownership
Funds ownership: 105.03% → 104.64% (-0.39%)
14% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 78
68% less call options, than puts
Call options by funds: $238K | Put options by funds: $734K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$14.1M |
| 2 |
Two Sigma Investments
New York
|
+$10.2M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$8.25M |
| 4 |
RA
Royce & Associates
New York
|
+$7.8M |
| 5 |
Two Sigma Advisers
New York
|
+$7.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$35M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.3M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$23.3M |
| 4 |
Goldman Sachs
New York
|
-$7.95M |
| 5 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$6.51M |
IRWD Hedge Fund Activity: Q1 2022 in Review
221 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2022, worth a combined $2.09B — up 4.6% from $2B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IRWD positions and 29 closed out — a net gain of 10 holders — while 67 added to existing stakes and 78 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $14.1M. The largest seller was Camber Capital Management, exiting entirely with an estimated $35M sold.
- 221 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2022, up from 212 in Q4 2021.
- Funds reported $2.09B of Ironwood Pharmaceuticals stock for Q1 2022, up 4.6% quarter-over-quarter.
- 39 funds opened new Ironwood Pharmaceuticals positions in Q1 2022 and 29 closed out, a net change of +10 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2022 was Morgan Stanley, an estimated $14.1M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2022 was Camber Capital Management, an estimated $35M sold.
Based on aggregated 13F filings for Q1 2022.